Drug Profile
Rosomidnar liposomal - Sierra Oncology
Alternative Names: PNT-2258Latest Information Update: 22 Jul 2022
Price :
$50
*
At a glance
- Originator ProNAi Therapeutics
- Developer Sierra Oncology
- Class Antineoplastics; Oligonucleotides
- Mechanism of Action Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma; Richter's syndrome; Solid tumours
Most Recent Events
- 22 Jul 2022 Discontinued - Phase-I for Solid tumours in USA (IV)
- 22 Jul 2022 Discontinued - Phase-II for Diffuse large B cell lymphoma (Late-stage disease, Recurrent, Treatment-resistant) in USA (IV)
- 22 Jul 2022 Discontinued - Phase-II for Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (IV)